New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X
Abstract EPNs comprise a heterogeneous group of neuroepithelial tumors, accounting for about 10% of all intracranial tumors in children and up to 30% of brain tumors in those younger than 3 years. Actually, the pattern therapy for low-grade EPNs includes complete surgical resection followed by radia...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/384af2c64a0143f7b07d35ffbf8a2408 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:384af2c64a0143f7b07d35ffbf8a2408 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:384af2c64a0143f7b07d35ffbf8a24082021-12-02T15:10:04ZNew therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X10.1038/s41598-019-45799-42045-2322https://doaj.org/article/384af2c64a0143f7b07d35ffbf8a24082019-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-019-45799-4https://doaj.org/toc/2045-2322Abstract EPNs comprise a heterogeneous group of neuroepithelial tumors, accounting for about 10% of all intracranial tumors in children and up to 30% of brain tumors in those younger than 3 years. Actually, the pattern therapy for low-grade EPNs includes complete surgical resection followed by radiation therapy. Total surgical excision is often not possible due to tumor location. The aim of this study was to evaluate, for the first time, the anti-tumor activity of Amblyomin-X in 4 primary cultures derived from pediatric anaplastic posterior fossa EPN, Group A (anaplastic, WHO grade III) and one primary culture of a high grade neuroepithelial tumor with MN1 alteration, which was initially misdiagnosed as EPN: i) by in vitro assays: comparisons of temozolomide and cisplatin; ii) by intracranial xenograft model. Amblyomin-X was able to induce cell death in EPN cells in a more significant percentage compared to cisplatin. The cytotoxic effects of Amblyomin-X were not detected on hFSCs used as control, as opposed to cisplatin-treatment, which promoted a substantial effect in the hAFSCs viability. TEM analysis showed ultrastructural alterations related to the process of cell death: mitochondrial degeneration, autophagosomes and aggregate-like structures. MRI and histopathological analyzes demonstrated significant tumor mass regression. Our results suggest that Amblyomin-X has a selective effect on tumor cells by inducing apoptotic cell death and may be a therapeutic option for Group AEPNs.Lorena Favaro PavonDavid CapperTatiana Tais SibovSilvia Regina Caminada de ToledoUlrich-W. ThomaleJean Gabriel de SouzaFrancisco Romero CabralCarolina Maria BerraMarcos Devanir Silva da CostaJardel Mendonça NiçacioPatrícia Alessandra DastoliDaniela Mara de OliveiraSuzana M. F. MalheirosEdgar Ferreira da CruzJackeline Moraes MalheirosSérgio Mascarenhas de OliveiraNasjla Saba SilvaAntonio Sérgio PetrilliAndrea Maria CappellanoMilena Colò BrunialtiReinaldo SalomãoManoel A. de Paiva NetoAna Marisa Chudzinski-TavassiSérgio CavalheiroNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 9, Iss 1, Pp 1-10 (2019) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Lorena Favaro Pavon David Capper Tatiana Tais Sibov Silvia Regina Caminada de Toledo Ulrich-W. Thomale Jean Gabriel de Souza Francisco Romero Cabral Carolina Maria Berra Marcos Devanir Silva da Costa Jardel Mendonça Niçacio Patrícia Alessandra Dastoli Daniela Mara de Oliveira Suzana M. F. Malheiros Edgar Ferreira da Cruz Jackeline Moraes Malheiros Sérgio Mascarenhas de Oliveira Nasjla Saba Silva Antonio Sérgio Petrilli Andrea Maria Cappellano Milena Colò Brunialti Reinaldo Salomão Manoel A. de Paiva Neto Ana Marisa Chudzinski-Tavassi Sérgio Cavalheiro New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X |
| description |
Abstract EPNs comprise a heterogeneous group of neuroepithelial tumors, accounting for about 10% of all intracranial tumors in children and up to 30% of brain tumors in those younger than 3 years. Actually, the pattern therapy for low-grade EPNs includes complete surgical resection followed by radiation therapy. Total surgical excision is often not possible due to tumor location. The aim of this study was to evaluate, for the first time, the anti-tumor activity of Amblyomin-X in 4 primary cultures derived from pediatric anaplastic posterior fossa EPN, Group A (anaplastic, WHO grade III) and one primary culture of a high grade neuroepithelial tumor with MN1 alteration, which was initially misdiagnosed as EPN: i) by in vitro assays: comparisons of temozolomide and cisplatin; ii) by intracranial xenograft model. Amblyomin-X was able to induce cell death in EPN cells in a more significant percentage compared to cisplatin. The cytotoxic effects of Amblyomin-X were not detected on hFSCs used as control, as opposed to cisplatin-treatment, which promoted a substantial effect in the hAFSCs viability. TEM analysis showed ultrastructural alterations related to the process of cell death: mitochondrial degeneration, autophagosomes and aggregate-like structures. MRI and histopathological analyzes demonstrated significant tumor mass regression. Our results suggest that Amblyomin-X has a selective effect on tumor cells by inducing apoptotic cell death and may be a therapeutic option for Group AEPNs. |
| format |
article |
| author |
Lorena Favaro Pavon David Capper Tatiana Tais Sibov Silvia Regina Caminada de Toledo Ulrich-W. Thomale Jean Gabriel de Souza Francisco Romero Cabral Carolina Maria Berra Marcos Devanir Silva da Costa Jardel Mendonça Niçacio Patrícia Alessandra Dastoli Daniela Mara de Oliveira Suzana M. F. Malheiros Edgar Ferreira da Cruz Jackeline Moraes Malheiros Sérgio Mascarenhas de Oliveira Nasjla Saba Silva Antonio Sérgio Petrilli Andrea Maria Cappellano Milena Colò Brunialti Reinaldo Salomão Manoel A. de Paiva Neto Ana Marisa Chudzinski-Tavassi Sérgio Cavalheiro |
| author_facet |
Lorena Favaro Pavon David Capper Tatiana Tais Sibov Silvia Regina Caminada de Toledo Ulrich-W. Thomale Jean Gabriel de Souza Francisco Romero Cabral Carolina Maria Berra Marcos Devanir Silva da Costa Jardel Mendonça Niçacio Patrícia Alessandra Dastoli Daniela Mara de Oliveira Suzana M. F. Malheiros Edgar Ferreira da Cruz Jackeline Moraes Malheiros Sérgio Mascarenhas de Oliveira Nasjla Saba Silva Antonio Sérgio Petrilli Andrea Maria Cappellano Milena Colò Brunialti Reinaldo Salomão Manoel A. de Paiva Neto Ana Marisa Chudzinski-Tavassi Sérgio Cavalheiro |
| author_sort |
Lorena Favaro Pavon |
| title |
New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X |
| title_short |
New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X |
| title_full |
New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X |
| title_fullStr |
New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X |
| title_full_unstemmed |
New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X |
| title_sort |
new therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a kunitz-type molecule, amblyomin-x |
| publisher |
Nature Portfolio |
| publishDate |
2019 |
| url |
https://doaj.org/article/384af2c64a0143f7b07d35ffbf8a2408 |
| work_keys_str_mv |
AT lorenafavaropavon newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT davidcapper newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT tatianataissibov newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT silviareginacaminadadetoledo newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT ulrichwthomale newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT jeangabrieldesouza newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT franciscoromerocabral newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT carolinamariaberra newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT marcosdevanirsilvadacosta newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT jardelmendoncanicacio newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT patriciaalessandradastoli newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT danielamaradeoliveira newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT suzanamfmalheiros newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT edgarferreiradacruz newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT jackelinemoraesmalheiros newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT sergiomascarenhasdeoliveira newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT nasjlasabasilva newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT antoniosergiopetrilli newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT andreamariacappellano newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT milenacolobrunialti newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT reinaldosalomao newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT manoeladepaivaneto newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT anamarisachudzinskitavassi newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx AT sergiocavalheiro newtherapeutictargetforpediatricanaplasticependymomacontrolstudyofantitumoractivitybyakunitztypemoleculeamblyominx |
| _version_ |
1718387744922664960 |